

Novel therapeutic antibody for multiple myeloma


-An antibody that specifically binds to CD98hc expressed in multiple myeloma-

Keywords: multiple myeloma, cancer immunotherapy, antibody therapy, glycosylation, CD98 heavy chain

Kana Hasegawa (Cellular Immunotherapy, IFRc), Naoki Hosen (IFRc/Graduate school of Medicine, Osaka University), and their research group found;

- A new antibody R8H283 recognizes CD98hc, which is ubiquitously expressed in all hematopoietic cells, but specifically binds to multiple myeloma
- The glycoforms of CD98hc present on normal leukocytes were distinct from those present on MM cells, which may explain the lack of R8H283 reactivity to normal leukocytes.
- R8H283 is a candidate for mAb-based therapies for MM.

Their findings showed that a cancer-specific conformational epitope in a ubiquitous protein, which cannot be identified by transcriptome or proteome analyses, can be found by extensive screening of primary human tumor samples.



- Journal: *Science Translational Medicine* (Feb. 17, 2022 online)
- Title: “Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain”
- Authors: Kana Hasegawa, Shunya Ikeda, Moto Yaga, Kouki Watanabe, Rika Urakawa,...Naoki Hosen* (*corresponding)
- DOI: <https://doi.org/10.1126/scitranslmed.aax7706>